Alzheimer’s disease (AD), the most common cause of dementia affecting over 13 million people worldwide, is characterized by the accumulation of amyloid-β (Aβ) aggregates, [1,2] the appearance of hyperphosphorylated Tau protein (p-Tau), [3] synaptic dysfunction, [4] neuroinflammation, [5] structural cerebrovascular alterations, and early deficits in cerebral glucose uptake and cerebral blood flow responses [6]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.